The Sudeep Pharma IPO GMP is currently one of the most discussed topics among investors, especially those tracking pharmaceutical and specialty chemical IPOs. With strong fundamentals and a sizable issue size, the IPO has created notable curiosity in the grey market.
Sudeep Pharma is launching a ₹895 crore IPO, comprising a fresh issue worth ₹95 crore and an offer for sale (OFS) of ₹800 crore. The IPO opened for bidding on November 21, 2025, and will close on November 25, 2025. The allotment date is scheduled for November 26, 2025, while the expected listing date on both NSE and BSE is November 28, 2025.
The price band for Sudeep Pharma IPO is set between ₹563 – ₹593 per share, with a minimum lot size of 25 shares, requiring a retail investment of ₹14,825 at the upper price band. For high-net-worth categories, the minimum investment for sNII is ₹2,07,550 (14 lots) and ₹10,08,100 (68 lots) for bNII.
As interest continues to build, the Sudeep Pharma IPO GMP is being actively watched as a potential indicator of post-listing sentiment. While GMP is not an official metric, it often reflects investor expectations and early demand.
With its industry presence, growth potential, and strong subscription buzz, the Sudeep Pharma IPO remains one to track closely—especially for investors looking at pharmaceutical and speciality chemical space.
Stay tuned for the latest updates on the Sudeep Pharma IPO GMP, and listing performance.
Post a Comment